AB
The company develops orally available immunotherapeutic drugs that utilize immunomodulation to treat severe infections and cancer. By focusing on anti-infective drug discovery, it provides the medical industry with effective therapeutic options to combat urgent global health challenges.
Updated 20 months ago
Funding
$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NC
Funding rounds are not available yet.
Founders
Product
Features
- The company develops orally available immunotherapeutic drugs that utilize immunomodulation to treat severe infections and cancer. By focusing on anti-infective drug discovery, it provides the medical industry with effective therapeutic options to combat urgent global health challenges.